The global neuroscience antibodies and assays market size was USD 3.20 Billion in 2020 and is expected to register a CAGR of 10.4% during the forecast period. Rising healthcare burden of neurological disorders, increasing demand for antibodies due to advancements in drug discovery, growing investment in neuroscience research, and rapid advancements in molecular and cellular neuroscience research are key factors expected to drive market revenue growth over the forecast period. Increasing automation of high-throughput screening and development of advanced software and solutions for data management to enable efficient research activities are also expected to contribute to revenue growth of the market going ahead.
Neuroscience is a multidisciplinary field of science concerned with the structure and function of the nervous system. Neuroscience comprises an integrated analysis of multiple cell types, tissues, and organs through the application of diverse techniques. Recent advancements in neuroscience have resulted in increased reliance on antibodies and immunodetection. Neuroscience antibodies can help in identifying and elucidating reactions on cellular, molecular, and biochemical levels. Increasing screening and recognition of roles of anti-brain specific autoantibodies in human neurological disorders have accelerated neuroscience research. Antibody-based methods are extensively used for localizing, isolating, and characterizing target proteins that are majorly used in neuroscience research. The advent of customized antibodies in precision medicine and early and accurate diagnosis of neurological disorders has further accelerated neuroscience antibody research and this trend is expected to be prevalent going ahead. Antibody-based approaches are crucial tools in cellular and molecular neuroscience and has led to in-depth knowledge of protein content, distribution, function, and structure. Antibodies such as phosphor-specific antibodies that are widely applicable in research studies of various pathways in different neurological disease are the most common bio-reagents used by researchers. Antibodies targeting specific neurological conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and other neurological diseases are widely available in the market. Rising global prevalence of Alzheimer’s disease and Parkinson’s disease is expected to boost demand for these antibodies to understand the progression and develop effective treatment regimens.
Request a Sample@ https://qyresearchmedical.com/sample/118924
The discovery of novel potential drug targets, structural proteins, and signaling molecules in the brain has led to a sharp increase in demand for high-quality neuroscience antibodies and this is expected to drive revenue growth of the market over the forecast period. Increasing R&D activities and rapid developments in pharmaceutical and biotechnology sectors are also expected to contribute to market growth going ahead. However, stringent norms implemented by regulatory authorities and rising incidence of adverse immune response against antibodies are expected to restrain market growth to a certain extent over the forecast period.
Driver: Increasing prevalence of neurological disorders such as Alzheimer’s disease is a key factor driving revenue growth
According to the World Health Organization, millions of individuals worldwide are affected by neurological disorders annually. Neurological disorders such as epilepsy, Alzheimer’s disease, multiple sclerosis, stroke, Parkinson’s disease, and traumatic brain injury have become more prevalent across the globe and are considered as major public health problems. Over the recent past, neurological disorders have become the second leading cause of death and number one cause of disability-adjusted life year. Increasing incidence of these neurological disorders in both developed and developing countries has propelled the research and development activities in the field of neuroscience. Rising demand for neuroscience antibodies in drug discovery and development of more effective therapeutic regimens is expected to drive revenue growth of the market over the forecast period.
Restraint: Increasing cases of adverse immune response against antibodies is a key factor restraining market growth
Antibodies directed against neurological disorders have been successful in managing and treating the condition. However, increasing cases of inflammatory side effects caused by these antibodies have been registered. This has led to the need for more research and work to improve and enhance potency of the antibodies without causing inflammatory side effects. This is expected to restrain market growth to a certain extent over the forecast period. In addition, time-intensive regulatory approval processes and stringent laws implemented by regulatory authorities regarding production and administration of these antibodies are expected to further hamper market growth to a significant extent during the forecast period.
Based on product, the global neuroscience antibodies and assays market has been segmented into consumables and instruments. Consumables can be further segmented into reagents, antibodies, and assay kits. Consumables segment is expected to account for largest revenue share over the forecast period owing to increasing demand and usage of consumables and frequent purchases. Rapid progress in genomics and proteomics research have been boosting demand for assay kits and reagents and this is expected contribute to revenue growth of this segment. Increasing availability of antibodies for neuroscience research and in developing drugs and therapeutics for treatment of neurological disorders is expected to drive growth of antibodies segment and in turn fuel revenue growth of consumables segment going ahead.
Based on technology, the global neuroscience antibodies and assays market has been segmented into immunoassays, molecular diagnostics, clinical chemistry, and others. Immunoassays segment is expected to register robust revenue CAGR over the forecast period. Growth can be attributed to rapid development of novel antibodies and assays for immunoassays, technological upgrades in immunoassays, and growing investment in research and development activities. Rising healthcare burden of neurological diseases, increasing application of immunoassays to monitor therapeutic drug doses and effectiveness, and growing use in pharmacokinetic and other studies during drug research and development are key factors expected to drive revenue growth of this segment over the forecast period.
Based on application, the global neuroscience antibodies and assays market has been segmented into research, in vitro diagnostics, and drug discovery & development. In vitro diagnostic application segment is expected to register significant revenue growth over the forecast period, attributable to increasing global prevalence of neurological disorders and brain injuries. Rising demand for more efficient detection of diseases, complications, and infections and for monitoring overall health of patients to treat neurological disorders is also expected to contribute to revenue growth of this segment going ahead.
Based on end-use, the global neuroscience antibodies and assays market has been segmented into pharmaceutical & biotechnology companies, academic & research institutes, and hospitals & diagnostic centers. Pharmaceutical and biotechnology companies are expected to account for a robust revenue share in the global market over the forecast period. Growth can be attributed to rapidly rising demand for neuroscience antibodies in drug discovery and development, increasing R&D investment and expenditure for quality control and quality assurance of neuroscience antibodies and assays kits, and advancement in proteomics and genomics research. The discovery of novel drug target and structural proteins in the brain and rising demand for neuroscience antibodies for research on neurological disease pathways are also expected to contribute significantly to revenue growth of this segment.
Based on regional analysis, North America is expected to account for largest market share in terms of revenue in the global market owing to increasing investment and expenditure for structure-based drug design and development, rapid progress in proteomics and genomics, increasing elderly population and rising incidence of neurological disorders, and robust presence of key players in the region. Existence of state-of-the-art healthcare infrastructure, growth of the biopharmaceutical sector, and rising financial support from governments are also expected to drive revenue growth of the market in the region.
Asia Pacific is expected to register robust revenue CAGR over the forecast period owing to increasing financial support and funding by governments and other healthcare organizations to accelerate development of new treatment approaches and assays for neurological disorders. Rising prevalence of neurological conditions such as depression, dementia, Alzheimer’s disease, and Parkinson’s disease and increasing research and development activities in the biopharmaceutical sector in countries in the region are key factors expected to drive market growth going ahead.
The global neuroscience antibodies and assays market is highly fragmented with a number of players operating on global and regional levels. Key players are focused on R&D activities, product advancement, and strategic alliances such as mergers and acquisitions, collaborations, and partnerships to cater to growing consumer demand. Prominent companies operating in the market include Thermo Fisher Scientific, Inc., Abcam, Bio-Rad, Merck KGaA, BioLegend, Cell Signaling Technology, F. Hoffmann-La Roche, GenScript, Rockland Immunochemicals, Santa Cruz Biotechnology, Siemens, and Tecan.
Some key developments in the market:
- In September 2020, Siemens Healthineers announced a collaboration agreement with Novartis Pharma AG for designing, development, and commercialization of diagnostic tests for pipeline therapeutic products of Novartis. The pilot program will focus on developing serum Neurofilament Light Chain (NfL) immunoassay for patients suffering from multiple sclerosis and other neurological diseases.
- In April 2021, Twist Bioscience Corporation, which offers high-quality synthetic DNA using its silicon platform, announced entering into partnership with multiple academic laboratories at Stanford University that will allow the company to access the former’s innovative antibody discovery and optimization services and its “Library of Libraries” to accelerate antibody discovery for a broad spectrum therapeutic targets. Under the initiative, the initial project will focus on discovery of novel antibodies to a specific neuroscience target from neurology lab at Stanford University School of Medicine.
- In April 2021, Committee for Medicinal Products for Human Use (CHMP) of European Medicine Agency recommended EU approval for Roche’s ENSPRYNG as the first subcutaneous option for patients suffering from anti-aquaporin-4 antibody (AQP4-IgG) seropositive Neuromyelitis Optica Spectrum Disorder (NMOSD). The treatment can be administered to adults and adolescents aged 12 years and older as a monotherapy or in combination with immunosuppressive therapy.
Segments Covered in the Report:
This report offers historical data and forecasts revenue growth at a global, regional, and country level, and provides analysis of the market trends in each of the segments from 2019 to 2030. For this study, Reports and Data has segmented the global neuroscience antibody and assays market based on product, technology, application, end-use, and region:
Neuroscience Antibodies and Assays Market Report Scope
Segments covered By Product Outlook, Technology Outlook, Application Outlook, End-use Industry Outlook, Regional Outlook
By Product Outlook
By Technology Outlook
Others Immunoassays Technologies
By Application Outlook
In Vitro Diagnostics
Drug Discovery and Development
By End-use Industry Outlook
Pharmaceutical and Biopharmaceutical Companies
Academic and Research Institutes
Hospital and Diagnostic Centers
Middle East & Africa
Buy quantitative research Report at discounted price – USD 1500 https://qyresearchmedical.com/report/checkout/118924/1500
You can place an order or ask any questions, please feel free to contact email@example.com | +1 9197 992 333
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover North America, Europe, Latin America, Middle East and Africa, Asia- Pacific.
For Latest Update Follow Us: